Sanofi (SNY)

Sanofi (SNY) stock research: performance, analysts' price targets, earnings, revenue and margins, technicals and insider trades.

Sanofi gains as vaccine approval stays in focus

Sanofi is up 1.2% today as the EU approval of its VaxRabeo rabies vaccine remains the clearest recent company news. The stock is outperforming a weak market, with its next report due Feb 4, 2027, before the open.

Published 2026-11-20 18:02:34 UTC.